AllianceBernstein
GYRE icon

AllianceBernstein’s Gyre Therapeutics GYRE Stock Holding History

AllianceBernstein’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Buy
24,590
+2,760
+13% +$18.8K ﹤0.01% 3186
2026
Q1 		$154K Hold
21,830
– – ﹤0.01% 3103
2025
Q4 		$154K Hold
21,830
– – ﹤0.01% 3111
2025
Q3 		$163K Buy
21,830
+1,900
+10% +$14.4K ﹤0.01% 3125
2025
Q2 		$146K Buy
+19,930
New +$174K ﹤0.01% 3116
2019
Q2 		– Sell
-1,827
Closed -$111K – 3162
2019
Q1 		$111K Sell
1,827
-440
-19% -$28.3K ﹤0.01% 3001
2018
Q4 		$134K Hold
2,267
– – ﹤0.01% 2958
2018
Q3 		$183K Hold
2,267
– – ﹤0.01% 3005
2018
Q2 		$198K Buy
+2,267
New +$398K ﹤0.01% 2973
2014
Q2 		– Sell
-31
Closed -$114K – 3500
2014
Q1 		$114K Sell
31
-5
-14% -$18.5K ﹤0.01% 2945
2013
Q4 		$119K Sell
36
-8
-18% -$31.5K ﹤0.01% 2901
2013
Q3 		$184K Sell
44
-3
-6% -$12.1K ﹤0.01% 2872
2013
Q2 		$157K Buy
+47
New +$179K ﹤0.01% 2887

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein's GYRE Position: Q2 2026 in Review

AllianceBernstein increased its Gyre Therapeutics (GYRE) stake by 13% in Q2 2026, buying an estimated $18.8K and bringing the position to 24,590 shares worth $171K. The position accounts for ﹤0.01% of the portfolio, ranked #3186.

AllianceBernstein first reported a position in GYRE in Q2 2013 and has held it in 13 quarters since. The position peaked at $198K in Q2 2018. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • AllianceBernstein held 24,590 shares of Gyre Therapeutics worth $171K as of Q2 2026.
  • AllianceBernstein bought 2,760 Gyre Therapeutics shares in Q2 2026, an estimated $18.8K.
  • Gyre Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3186 holding.
  • AllianceBernstein first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 13 quarters since.
  • AllianceBernstein's Gyre Therapeutics position peaked at $198K in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.